#1292ef

Eisai Us

#f9f9f9

Neriman Botas

Lucille Naclerio

Simon Thomas

Leigh Steele

Shaji Procida

Dominick Favorito

Kathy Stenson

Paul Mcginley

Jaideep Singh

Ivan Cheung

Dan Li

Nandan Shah

Kim Onal

Bart Alvarez

EVERYTHING WE DO
IS GUIDED BY
human health care (hhc)
LEARN ABOUT hhc
We are honored to be included in the Medical Care Category
read more
read more
From TIME . ? 2023 TIME USA LLC
All rights reserved. Used under license.
TRENDING TOPICS
Check out what?s new with Eisai. Explore content that highlights our
commitment to pursuing breakthrough solutions and medicines to enrich people?s lives.
Press Release
Press Release | 
December 08, 2023
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA? (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Read more >
Press Release
Press Release | 
October 25, 2023
EISAI PRESENTS NEW LEQEMBI? (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Read more >
Press Release
Press Release | 
October 24, 2023
LEQEMBI? (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023
Read more >
Press Release
Press Release | 
October 15, 2023
EISAI TO PRESENT NEW DATA FROM LEQEMBI? (LECANEMAB-IRMB) PHASE 3 CLARITY AD STUDY AND OTHER ALZHEIMER'S DISEASE PIPELINE RESEARCH AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Read more >
latest news
latest news
GROWING HOPE
THROUGH HISTORY
learn more about our research

Eisai adheres strictly to the rules and regulations set forth by the Physician Payments Sunshine Act. Find FAQs regarding Sunshine and Open Payments here.

Eisai US